IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of molecular sciences Jg. 22; H. 21; S. 11848
Hauptverfasser:	Harper, Taylor A., Bacot, Silvia M., Fennell, Christie Jane, Matthews, Rebecca L., Zhu, Christina, Yue, Peng, Benton, Alexander, Friedman, Devira, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 31.10.2021 MDPI
Schlagworte:	Apoptosis Cancer Clinical trials Cytokines FDA approval Humans Immunotherapy Interferon-gamma - immunology Interleukin-10 - immunology Interleukin-2 Receptor alpha Subunit - immunology Ki-67 Antigen - immunology Lymphocyte Activation - drug effects Lymphocytes MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - immunology Melanoma Nivolumab - pharmacology T-Lymphocytes - immunology Targeted cancer therapy STAT3 pathway nivolumab AKT serine–threonine kinase pathway MAP kinase pathway cytokines T cells interleukin 10
ISSN:	1422-0067, 1661-6596, 1422-0067
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!